These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 33820810)

  • 1. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
    Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
    Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
    Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
    Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
    Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
    Tarhini AA; Kang N; Lee SJ; Hodi FS; Cohen GI; Hamid O; Hutchins LF; Sosman JA; Kluger HM; Eroglu Z; Koon HB; Lawrence DP; Kendra KL; Minor DR; Lee CB; Albertini MR; Flaherty LE; Petrella TM; Streicher H; Sondak VK; Kirkwood JM
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.
    Monson KR; Ferguson R; Handzlik JE; Xiong J; Dagayev S; Morales L; Chat V; Bunis A; Sreenivasaiah C; Dolfi S; Tenney DJ; Shao Y; Osman I; Weber JS; Kirchhoff T
    Clin Cancer Res; 2024 Oct; 30(19):4412-4423. PubMed ID: 39115425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Kim YJ; Lee M; Kim EH; Lee S; Park S; Hong MH; Shin SJ; Jung I; Lee CK; Lee CS
    Cancer Lett; 2024 Aug; 596():216998. PubMed ID: 38830470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors: A Population-based Study Using SEER-Medicare Data.
    Tully KH; Cone EB; Cole AP; Sun M; Chen X; Marchese M; Roghmann F; Kilbridge KL; Trinh QD
    Am J Clin Oncol; 2021 Aug; 44(8):413-418. PubMed ID: 34081033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
    Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
    Langan EA; Budner K; Zillikens D; Terheyden P
    Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
    Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
    Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
    Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
    Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
    Nuñez NG; Berner F; Friebel E; Unger S; Wyss N; Gomez JM; Purde MT; Niederer R; Porsch M; Lichtensteiger C; Kramer R; Erdmann M; Schmitt C; Heinzerling L; Abdou MT; Karbach J; Schadendorf D; Zimmer L; Ugurel S; Klümper N; Hölzel M; Power L; Kreutmair S; Capone M; Madonna G; Cevhertas L; Heider A; Amaral T; Hasan Ali O; Bomze D; Dimitriou F; Diem S; Ascierto PA; Dummer R; Jäger E; Driessen C; Levesque MP; van de Veen W; Joerger M; Früh M; Becher B; Flatz L
    Med; 2023 Feb; 4(2):113-129.e7. PubMed ID: 36693381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.